Search

everythinglearnresearchcommunity

for

Search:↓

The user shared their 5-year hair recovery journey using finasteride, RU58841, dutasteride, minoxidil, and microneedling, noting mixed progress but overall improvement. They regret not starting treatment earlier and recently received positive health feedback from their doctor.

A human trial involving verteporfin for hair regeneration, with the results showing some regrowth of 1-2 hairs in an area where a follicular unit was extracted. The conversation also suggested that future studies should involve higher doses and more frequent injections.

A user has been using dutasteride, RU58841, minoxidil, and ketoconazole for 2 years with no progress and worsening hair recession. They seek advice on how to proceed.

The user shared progress pictures over four months using topical finasteride, topical and oral minoxidil, topical RU58841 daily, and oral dutasteride once a week. The pictures are spaced about a month apart.

Spironolactone, finasteride, and dutasteride are discussed for hair maintenance, with concerns about testosterone and side effects like gynecomastia. Spironolactone is noted for use in both bodybuilding and hormone therapy, with low doses considered for minimizing side effects.

The conversation is optimistic about future hair loss treatments, highlighting Veradermics, Breezula, and PP405 as promising options expected by 2027-2028. The user expresses hope that these developments will prevent future generations from experiencing the same struggles with hair loss.

A user with AGA uses topical spironolactone 2% due to side effects from the oral form and is concerned about its use during conception and breastfeeding. They seek alternatives to prevent AGA relapse while planning pregnancy and after childbirth.

The user experienced significant hair regrowth using dutasteride (0.5 mg three times a week) and RU58841 (5% once a day), with no side effects reported from RU58841. They are considering increasing the RU58841 dose or adding minoxidil for further improvement.

Finasteride can reduce neuroactive steroids, causing side effects like depression, anxiety, and sexual dysfunction. Some users experience persistent symptoms after stopping finasteride, while others use alternative treatments like topical solutions.

Pregnancy can temporarily reverse hair loss in women, but attempts to mimic pregnancy hormones with treatments like contraceptive pills, spironolactone, estradiol, progesterone, finasteride, and minoxidil have been ineffective. The discussion highlights the need for research into the hormonal mechanisms of pregnancy that affect hair regrowth.

A user, almost 50, has been using finasteride for 30 years and recently added oral dutasteride to address hair recession. They are now trying a new treatment stack including Minoxidil, Dutasteride, Melatonin, Rosemary oil, and Bimatoprost, along with derma stamping and Ketoconazole shampoo.

The conversation discusses using cyproterone temporarily to reverse hair loss, followed by finasteride to maintain regrowth. Concerns about cyproterone's side effects, such as lowering testosterone and potential health risks, are raised, with alternatives like spironolactone suggested for androgen-related issues.

Latanoprost is discussed as a potential hair loss treatment, noted for its synergy with minoxidil and 5-AR inhibitors, but concerns include its effectiveness on scalp hair, cost, and potential skin darkening. Some users express interest in trying latanoprost or bimatoprost despite limited real-world evidence.

The user shared their 6-month progress using 0.25 mg finasteride, topical minoxidil, and dermastamping, noting good results but experiencing increased sleepiness. Another user suggested minoxidil might be causing the sleepiness, and the original poster considered adjusting their treatment.

The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.

The user plans to pause finasteride for two months to test its effects on mood and productivity, then switch to Pyrilutamide while monitoring hormone levels. Concerns are raised about potential hair loss and the effectiveness of Pyrilutamide compared to finasteride.

A user ordered a topical dutasteride gel with tretinoin for hair loss after unsatisfactory results with minoxidil and finasteride. Another user shared their experience with the same product, noting its pleasant smell and feel but difficulty in application and uncertainty about its absorption and frequency of use.

The user has been using finasteride, minoxidil, and Nizoral for 9 months with little progress in hair regrowth and is considering switching to dutasteride. They experience daily scalp pain and anxiety, and are exploring other treatments like Head & Shoulders and consulting a dermatologist.

A 26-year-old male has been using finasteride for 4.5 years to maintain hair and recently started taking dutasteride weekly due to increased hair shedding. He plans to gradually switch to dutasteride while monitoring side effects and hair changes.

User started using stemoxydine with minoxidil for mild hair recession and maintenance. Stemoxydine improves hair appearance and behavior, making it fuller and shinier.

A user in their mid-20s is considering using oral Dutasteride, prescribed by a dermatologist, alongside topical Minoxidil, Finasteride, biotin, and zinc for hair loss. Other users suggest Dutasteride is more effective than Finasteride for regrowth, despite not being approved for hair loss in the U.S.

Hair loss treatments Finasteride and Dutasteride are discussed, with emphasis on their safety and effectiveness. Users share frustration about fear-mongering and side effect discussions, suggesting trust in scientific studies and FDA approval.

The conversation discusses making homemade topical solutions of dutasteride or finasteride using tablets, with suggestions to use alternatives like MinoxidilMax or stemoxydine due to difficulties in formulation. Some users recommend sticking to oral pills for effectiveness and ease.

A user shared their successful hair regrowth journey using finasteride, oral minoxidil, and oral dutasteride, expressing gratitude for the support received. The conversation includes congratulations and encouragement from others.

A 23-year-old has been using finasteride 5mg daily since age 19 and added dutasteride 0.5mg twice a week to prevent hairline recession. They report no side effects and credit early treatment for maintaining their hair.

The conversation discusses the use of Finastopic, a carrier for finasteride solutions by Isdin, and compares it to a standard propylene glycol (PG) solution. The user was prescribed a 1% finasteride solution using Finastopic and has been using a self-compounded 0.025% topical finasteride with minoxidil.

The user is using finasteride 1mg every other day and seeks a topical solution to complement it, excluding minoxidil. They are considering various combinations of ingredients like finasteride, dutasteride, and tofacitinib, with options for nourishing oils and other additives.

The user is experiencing erectile dysfunction and decreased sperm quality from using Dutasteride for hair loss and is considering stopping it to improve fertility. They are exploring other treatments like Viviscal Men, Minoxidil, Revlan Red System, Fluridil, Nizoral, Stemoxydine, and Eucapil.

Finasteride and Dutasteride do not cause depression or "Post Finasteride Syndrome," with concerns often linked to the nocebo effect and preexisting mental health issues. The EU is unlikely to ban these drugs, but access may become more restricted due to ongoing debates.

The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.